corporate_fare

Kardigan Inc.

Address: 131 Oyster Point Boulevard Second Floor

Sponsor Overview

assignment

Specializations

Cardiomyopathy and Inherited Heart Muscle Disease

Kardigan Inc. focuses on symptomatic genetic and familial dilated cardiomyopathy, with research centered on the clinical burden of inherited cardiac muscle dysfunction and its impact on heart performance. The sponsor’s trial activity in this area reflects interest in conditions where structural and functional abnormalities of the heart lead to reduced efficiency and progressive symptoms.

Dilated cardiomyopathy
Genetic cardiomyopathy
Familial heart disease
Symptomatic cardiac impairment

Research in this field is directed toward improving understanding of heart function in patients with inherited disease patterns and persistent clinical symptoms.

Cardiac Function Assessment

The sponsor’s research includes evaluation of left ventricular performance and broader measures of cardiac function in affected participants. This area emphasizes clinical endpoints that capture how inherited cardiomyopathy influences the heart’s ability to pump effectively and maintain circulatory support.

Transthoracic echocardiogram
Heart pumping function
Ventricular performance
Cardiac structure and function

These interests align with monitoring changes in myocardial performance in patients living with progressive hereditary heart disease.

Exercise Capacity and Functional Status

Kardigan Inc. also studies exercise tolerance in participants with cardiomyopathy, reflecting attention to how cardiac disease affects physical performance and daily activity. This includes interest in objective measures of functional limitation in patients with symptomatic disease.

Cardiopulmonary exercise testing
Exercise performance
Functional limitation
Symptom-related exercise impairment

This therapeutic domain is closely tied to assessing the real-world impact of inherited heart disease on patient mobility and exertional capacity.

Cardiovascular Therapeutics

The sponsor’s clinical research includes investigation of danicamtiv in the setting of inherited dilated cardiomyopathy, indicating a strong therapeutic interest in treatments aimed at supporting compromised myocardial function. The research landscape is centered on cardiovascular disease management where improving heart performance is a key clinical objective.

Myocardial support
Inherited cardiovascular disease
Heart failure-related symptoms
Therapies for cardiomyopathy

Clinical activity in this area is concentrated in North America and multiple international research sites, with a focus on cardiovascular conditions affecting patients across diverse settings.

Trial Name	Country	Status
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).	Belgium Denmark France Hungary Italy Poland Spain Sweden The Netherlands	Recruiting
Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Trial of Ataciguat to Slow Progression and Improve Peak VO2 in Moderate Calcific Aortic Valve Stenosis	Austria Czechia France Norway Poland Portugal Spain	Not Yet Recruiting